Research collaboration identifies biomarker panel linked to melanoma patient survival

June 6, 2017, University College Dublin
Melanoma. Credit: UCD Conway

An international research collaboration led by University College Dublin (UCD), involving the UCD spin-out company OncoMark and Bellvitge Biomedical Research Institute in Barcelona, has identified a set of biomarkers strongly linked with survival in patients with melanoma that may help clinicians with treatment decisions.

The study has also identified several biomarkers of tumour development and progression that have never been linked to cutaneous until now.

Cutaneous melanoma is the most life-threatening form of skin cancer with rising incidence and mortality rates particularly in men over 55 years and women of all ages.

Currently, there are very limited tools available to help clinicians pinpoint the stage of the disease in a patient at the time of diagnosis. Clinicians make their diagnosis based on classical identifiers such as the thickness of the tumour.

Up until now, it has been problematic to identify early events during the development and progression of melanoma as studies used samples from tumour metastases rather than the primary tumour.

This study involved a comprehensive mapping of the extent of DNA methylation occurring at three distinct stages of development of this skin cancer; from benign nevi to malignant melanoma to metastatic melanoma.

DNA methylation is a natural chemical change that results in genes being switched on or off. This epigenetic change does not alter the genetic code itself but affects how genes are read by cells and what proteins are made as a result.

The team have shown the importance of epigenomic regulation in triggering tumour spread by the way in which it can switch off certain cancer-related pathways and interrupt normal cell processes such as cell adhesion. When this occurs, can break away from each other and metastasise or travel away from the original location to other parts of the body.

Describing the significance of this study, Professor William Gallagher, UCD Professor of Cancer Biology at the UCD Conway Institute and Chief Scientific Officer at OncoMark said,

"This research highlights that this type of comprehensive, genome-wide DNA methylation mapping can provide insight to the transformation and aggressiveness of tumour cells. It has allowed us to identify a DNA methylation signature associated with patient survival and we are excited by the potential clinical utility of these biomarkers. They may provide clinicians with a powerful tool to stratify who have benign versus more aggressive types and allow them to tailor treatment accordingly."

According to Dr Manel Esteller (Bellvitge Biomedical Research Institute, Barcelona), co-lead author on the study:

"This study represents the most comprehensive epigenomic profiling assessment of well-described human melanomas. It verifies that DNA methylation biomarkers represent a valuable tool to identify potential protein biomarkers. This not only has implications for the clinical management of melanoma but several cancer types."

Dr Jasper Wooters, first author of the study, says,

"In this epigenomic melanoma study, we establish novel biomarkers to identify patients with good prognosis that do not necessarily need to undergo aggressive and expensive therapies. Importantly, some of these biomarkers can potentially be assessed non-invasively, using cell-free DNA in the serum of patients."

Explore further: A method for the diagnosis and prognosis of melanoma, the most aggressive skin cancer, is patented

More information: Jasper Wouters et al. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma, BMC Medicine (2017). DOI: 10.1186/s12916-017-0851-3

Related Stories

A method for the diagnosis and prognosis of melanoma, the most aggressive skin cancer, is patented

February 19, 2014
UPV/EHU researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate.This method will help not only in the more effective early detection ...

Epigenomic changes play an important role during the progression of melanoma

April 9, 2015
KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures. Melanoma, a type of skin cancer, is notoriously quick to metastasize and ...

A protein that defines the melanoma blueprint

November 18, 2016
The main goals of the Melanoma Group at the Spanish National Cancer Research Centre (CNIO) are to identify biomarkers of tumour progression and to validate novel therapeutic targets in melanoma. In particular, their research ...

Study reveals how melanoma spreads

February 8, 2017
Cancerous tumors are voracious. Once they have consumed all the oxygen and nutrients in the original tumor site, the cancer cells travel to other parts of the body (metastasize) to find more nourishment.

Melanoma research breakthrough gives hope for treatment

February 7, 2017
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.

Recommended for you

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

Study shows biomarker panel boosts lung cancer risk assessment for smokers

July 12, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international ...

Discovering the mechanisms that underlie prostate cancer

July 12, 2018
New research has uncovered insights into the mechanisms that underlie prostate cancer, providing potential targets for new cancer therapies.

New method reveals how well cancer drugs hit their targets

July 12, 2018
Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumour in real time, revealing which cells interact with the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.